Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 11, 2015, Pages 1351-1360

  Chan, Kuan Rong ^a   Ong, Eugenia Z ^b   Mok, Darren Zl ^a   Ooi, Eng Eong ^a,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Agency for Science   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

Author keywords

Antibody; Fc effector functions; Fc receptors; neutralization; therapeutics

Indexed keywords

BEVACIZUMAB; CETUXIMAB; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY CD28; PALIVIZUMAB; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP 1; RITUXIMAB; STAT1 PROTEIN; TGN 1412; TRASTUZUMAB; CYTOKINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTATION; BINDING AFFINITY; BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; CYTOKINE STORM; DENGUE VIRUS; DRUG EFFICACY; EBOLAVIRUS; ENDOCYTOSIS; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; HENDRA VIRUS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; INNATE IMMUNITY; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS; VIRUS INFECTION; VIRUS NEUTRALIZATION; IMMUNOLOGY; METABOLISM; VIRUS DISEASES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; PHAGOCYTOSIS; RECEPTORS, IGG; VIRUS DISEASES;

EID: 84945444305     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1079127     Document Type: Review

References (92)

1. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514 (7520): 47-53
2. Zhu Z, Bossart KN, Bishop KA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 2008; 197 (6): 846-53
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3): 531-7
4. Thakkar S, Nanaware-Kharade N, Celikel R, et al. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering. Sci Rep 2014; 4: 3673
5. Jiang XR, Song A, Bergelson S, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10 (2): 101-11
6. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239 (4839): 476-81
7. Linn ML, Aaskov JG, Suhrbier A. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J Gen Virol 1996; 77 (Pt 3): 407-11
8. Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 1994; 68 (6): 3499-504
9. Robinson WE Jr, Montefiori DC, Mitchell WM, et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci USA 1989; 86 (12): 4710-14
10. Robinson WE Jr, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1 (8589): 790-4
11. DiLillo DJ, Ravetch JV. Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. Cancer Immunol Res 2015; 3 (7): 704-13
12. Nimmerjahn F, Gordan S, Lux A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 2015; 36 (6): 325-36
13. Ugolini S, Mondor I, Parren PW, et al. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997; 186 (8): 1287-98
14. de Rosny E, Vassell R, Jiang S, et al. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004; 78 (5): 2627-31
15. Thompson BS, Moesker B, Smit JM, et al. A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 2009; 5 (5): e1000453
16. Chan KR, Zhang SL, Tan HC, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 2011; 108 (30): 12479-84
17. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8 (1): 34-47
18. Iwashima M, Irving BA, van Oers NS, et al. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 1994; 263 (5150): 1136-9
19. Huang ZY, Hunter S, Kim MK, et al. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM-and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leuk Biol 2003; 73 (6): 823-9
20. Kant AM, De P, Peng X, et al. SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood 2002; 100 (5): 1852-9
21. Boruchov AM, Heller G, Veri MC, et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115 (10): 2914-23
22. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6 (4): 443-6
23. Zhang M, Zhang Z, Garmestani K, et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res 2004; 64 (16): 5825-9
24. Bulliard Y, Jolicoeur R, Windman M, et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210 (9): 1685-93
25. Wernersson S, Karlsson MC, Dahlstrom J, et al. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. J Immunol 1999; 163 (2): 618-22
26. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113 (16): 3716-25
27. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21 (21): 3940-7
28. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26 (11): 1789-96
29. Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006; 24 (18): 2885-90
30. Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68 (10): 1547-52
31. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27 (7): 1122-9
32. Liu Z, Gunasekaran K, Wang W, et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J Biol Chem 2014; 289 (6): 3571-90
33. Hiatt A, Bohorova N, Bohorov O, et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci USA 2014; 111 (16): 5992-7
34. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 2007; 179 (7): 4580-8
35. Zhu X, Meng G, Dickinson BL, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 2001; 166 (5): 3266-76
36. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176 (1): 346-56
37. Datta-Mannan A, Witcher DR, Tang Y, et al. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282 (3): 1709-17
38. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170 (7): 3528-33
39. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28 (2): 157-9
40. Ko SY, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014; 514 (7524): 642-5
41. Armitage CW, OMeara CP, Harvie MC, et al. Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens. Immunol Cell Biol 2014; 92 (5): 417-26
42. Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007; 196 (3): 416-24
43. Halstead SB, ORourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146 (1): 201-17
44. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hygiene 1988; 38 (2): 411-19
45. Guilliams M, Bruhns P, Saeys Y, et al. The function of Fcgamma receptors in dendritic cells and macrophages. Nature reviews. Immunology 2014; 14 (2): 94-108
46. Araki N, Hatae T, Furukawa A, Swanson JA. Phosphoinositide-3-kinase-independent contractile activities associated with Fcgamma-receptor-mediated phagocytosis and macropinocytosis in macrophages. J Cell Sci 2003; 116 (Pt 2): 247-57
47. Ganesan LP, Wei G, Pengal RA, et al. The serine/threonine kinase Akt Promotes Fc gamma receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase. J Biol Chem 2004; 279 (52): 54416-25
48. Huang ZY, Barreda DR, Worth RG, et al. Differential kinase requirements in human and mouse Fc-gamma receptor phagocytosis and endocytosis. J Leuk Biol 2006; 80 (6): 1553-62
49. Holl V, Hemmerter S, Burrer R, et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 2004; 173 (10): 6274-83
50. Chawla T, Chan KR, Zhang SL, et al. Dengue virus neutralization in cells expressing Fc gamma receptors. PLoS ONE 2013; 8 (5): e65231
51. Dai X, Jayapal M, Tay HK, et al. Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa. Blood 2009; 114 (2): 318-27
52. Furlan SN, Mandraju R, Brewer T, et al. Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. mAbs 2014; 6 (1): 108-18
53. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189 (2): 371-80
54. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med 2002; 195 (1): F1-3
55. Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune complexes. Front Immunol 2014; 5: 140
56. McEwan WA, Mallery DL, Rhodes DA, et al. Intracellular antibody-mediated immunity and the role of TRIM21. Bioessays 2011; 33 (11): 803-9
57. Mallery DL, McEwan WA, Bidgood SR, et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Nat Acad Sci USA 2010; 107 (46): 19985-90
58. Vaysburd M, Watkinson RE, Cooper H, et al. Intracellular antibody receptor TRIM21 prevents fatal viral infection. Proc Nat Acad Sci USA 2013; 110 (30): 12397-401
59. McEwan WA, Tam JC, Watkinson RE, et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 2013; 14 (4): 327-36
60. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110 (1): 71-9
61. Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 10 (10): 712-22
62. Chan KR, Ong EZ, Tan HC, et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Nat Acad Sci USA 2014; 111 (7): 2722-7
63. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci USA 2008; 105 (29): 10095-100
64. Cosman D, Fanger N, Borges L, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7 (2): 273-82
65. Rodrigo WW, Jin X, Blackley SD, et al. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006; 80 (20): 10128-38
66. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharmaceut Res 2010; 27 (5): 796-810
67. Morefield GL, Sokolovska A, Jiang D, et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005; 23 (13): 1588-95
68. Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173 (5): 3148-54
69. Macura N, Zhang T, Casadevall A. Dependence of macrophage phagocytic efficacy on antibody concentration. Infect Immun 2007; 75 (4): 1904-15
70. Lev A, Sigal L. Getting in front and behind the enemy lines to counter virus infection. Cell Host Microbe 2013; 13 (2): 121-2
71. Dhodapkar KM, Banerjee D, Connolly J, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 2007; 204 (6): 1359-69
72. Zornetzer GA, Frieman MB, Rosenzweig E, et al. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J Virol 2010; 84 (21): 11297-309
73. Majewski M, Bose TO, Sille FC, et al. Protein kinase C delta stimulates antigen presentation by Class II MHC in murine dendritic cells. Int Immunol 2007; 19 (6): 719-32
74. Tridandapani S, Siefker K, Teillaud JL, et al. Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem 2002; 277 (7): 5082-9
75. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291 (5503): 484-6
76. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313 (5787): 670-3
77. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204 (1): 11-15
78. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124 (2): 188-95
79. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Eng J Med 2006; 355 (10): 1018-28
80. Mandelboim O, Malik P, Davis DM, et al. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 1999; 96 (10): 5640-4
81. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983; 148 (5): 785-94
82. Milligan C, Richardson BA, John-Stewart G, et al. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 2015; 17 (4): 500-6
83. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5 (5): e1000433
84. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449 (7158): 101-4
85. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23 (8): 897-906
86. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004; 25 (3): 158-64
87. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002; 13 (6): 609-14
88. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994; 54 (7): 1753-9
89. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276 (9): 6591-604
90. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Nat Acad Sci USA 2006; 103 (11): 4005-10
91. Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 2011; 13 (6): R123
92. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277 (30): 26733-40